Trump Administration to Examine Ibogaine Research for PTSD Funding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PBM?
Source: stocktwits
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
U.S. Stock Futures Retreat Amid Renewed Geopolitical Tensions
- Futures Pullback: U.S. stock futures retreated early Monday after last week's record highs, with S&P 500 and Nasdaq futures down 0.6% and 0.7% respectively, indicating rising investor concerns over geopolitical risks.
- Strait of Hormuz Tensions: Iran's announcement to keep the critical shipping route restricted, coupled with President Trump's confirmation of seizing an Iranian cargo ship, has reignited market focus on oil price volatility, prompting renewed interest in oil-linked stocks like BATL and EONR.
- Psychedelic Stocks Surge: Following President Trump's executive order to expedite psychedelic drug approvals, stocks like Psyence Biomedical (PBM), Definium Therapeutics (DFTX), and Compass Pathways (CMPS) are gaining retail investor attention, reflecting a growing market interest in mental health treatments.
- Tesla's Positive Outlook: Tesla is on track for its first positive month this year, with Elon Musk downplaying competitive fears from China's BYD, emphasizing that execution, rather than competition, is the key challenge for the EV maker, showcasing the company's confidence in its future performance.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Trump to Sign Executive Order on Psychedelic Research
- Stock Surge: Psyence Biomedical Ltd. (PBM) shares closed over 100% higher on Thursday and continued to rally by 42% on Friday, indicating the company is on track for its best trading week in over two years, reflecting strong market interest in psychedelic research.
- Executive Order Impact: The Trump administration is expected to sign an executive order this week aimed at opening federal funding for research on PTSD and traumatic brain injuries, although ibogaine will remain classified as a Schedule I drug, indicating a cautious governmental approach to psychedelic research.
- Strategic Investment: Psyence highlighted its strategic investment in Psylabs, a biopharmaceutical company in Southern Africa specializing in the cultivation and extraction of nature-derived psychedelic active pharmaceutical ingredients, showcasing the company's long-term commitment to the psychedelic sector.
- Market Sentiment: Retail sentiment around PBM stock has remained in the 'extremely bullish' territory over the past 24 hours, with message volume jumping from 'high' to 'extremely high', indicating strong investor interest in the upcoming research opportunities.
See More
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
U.S. Stock Futures Retreat Amid Renewed Geopolitical Tensions
- Futures Pullback: U.S. stock futures retreated early Monday after last week's record highs, with S&P 500 and Nasdaq futures down 0.6% and 0.7% respectively, indicating rising investor concerns over geopolitical risks.
- Strait of Hormuz Tensions: Iran's announcement to keep the critical shipping route restricted, coupled with President Trump's confirmation of seizing an Iranian cargo ship, has reignited market focus on oil price volatility, prompting renewed interest in oil-linked stocks like BATL and EONR.
- Psychedelic Stocks Surge: Following President Trump's executive order to expedite psychedelic drug approvals, stocks like Psyence Biomedical (PBM), Definium Therapeutics (DFTX), and Compass Pathways (CMPS) are gaining retail investor attention, reflecting a growing market interest in mental health treatments.
- Tesla's Positive Outlook: Tesla is on track for its first positive month this year, with Elon Musk downplaying competitive fears from China's BYD, emphasizing that execution, rather than competition, is the key challenge for the EV maker, showcasing the company's confidence in its future performance.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Trump to Sign Executive Order on Psychedelic Research
- Stock Surge: Psyence Biomedical Ltd. (PBM) shares closed over 100% higher on Thursday and continued to rally by 42% on Friday, indicating the company is on track for its best trading week in over two years, reflecting strong market interest in psychedelic research.
- Executive Order Impact: The Trump administration is expected to sign an executive order this week aimed at opening federal funding for research on PTSD and traumatic brain injuries, although ibogaine will remain classified as a Schedule I drug, indicating a cautious governmental approach to psychedelic research.
- Strategic Investment: Psyence highlighted its strategic investment in Psylabs, a biopharmaceutical company in Southern Africa specializing in the cultivation and extraction of nature-derived psychedelic active pharmaceutical ingredients, showcasing the company's long-term commitment to the psychedelic sector.
- Market Sentiment: Retail sentiment around PBM stock has remained in the 'extremely bullish' territory over the past 24 hours, with message volume jumping from 'high' to 'extremely high', indicating strong investor interest in the upcoming research opportunities.
See More
